Prelude Therapeutics (PRLD) News Today $1.16 +0.05 (+4.50%) Closing price 04:00 PM EasternExtended Trading$1.16 +0.01 (+0.43%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMPAugust 19, 2025 | msn.comPrelude Therapeutics Pauses Intravenous SMARCA2 Degrader DevelopmentAugust 14, 2025 | msn.comPrelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comCan Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?August 11, 2025 | finance.yahoo.comPrelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher - Time to Buy?July 26, 2025 | marketbeat.comPrelude Therapeutics Incorporated (PRLD) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comPrelude Therapeutics Incorporated (PRLD) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLCJune 8, 2025 | marketbeat.comPrelude Therapeutics to Present at Major Healthcare Conferences in June 2025June 3, 2025 | msn.comPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesJune 2, 2025 | globenewswire.comPrelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challengesMay 28, 2025 | investing.comPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comPrelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025May 4, 2025 | msn.comBoxer Capital Management LLC Purchases New Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)May 4, 2025 | marketbeat.comRenaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD)May 4, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Prelude Therapeutics (NASDAQ:PRLD)May 1, 2025 | marketbeat.comPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comPrelude Therapeutics (PRLD) Projected to Post Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comPrelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer TherapiesApril 30, 2025 | msn.comPrelude Announces Presentations at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in StockMarch 28, 2025 | insidertrades.comPrelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 SharesMarch 15, 2025 | insidertrades.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)March 12, 2025 | markets.businessinsider.comPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)March 10, 2025 | markets.businessinsider.comPrelude Therapeutics sees cash runway into 2Q26March 10, 2025 | markets.businessinsider.comPrelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025March 10, 2025 | globenewswire.comPrelude Therapeutics to Present at Barclays Global Healthcare ConferenceMarch 6, 2025 | msn.comPrelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comInsider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires 10,000 Shares of StockJanuary 3, 2025 | insidertrades.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires $12,000.00 in StockJanuary 2, 2025 | marketbeat.comAndrew Combs Acquires 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) StockDecember 27, 2024 | insidertrades.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Acquires $82,200.00 in StockDecember 26, 2024 | marketbeat.comKrishna Vaddi Bought 4.9% More Shares In Prelude TherapeuticsDecember 22, 2024 | uk.finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Bryant David Lim Buys 25,000 SharesDecember 21, 2024 | insidertrades.comFueling growth: The Innovation Space powers breakthroughs in life sciences, clean technologies, and advanced materialsDecember 20, 2024 | bizjournals.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Acquires $22,750.00 in StockDecember 20, 2024 | marketbeat.comKrishna Vaddi Buys 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) StockDecember 20, 2024 | marketbeat.comPrelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527December 13, 2024 | msn.comPrelude Therapeutics (PRLD) Gets a Sell from Morgan StanleyDecember 12, 2024 | markets.businessinsider.comPrelude Therapeutics presents first interim data from trial of PRT2527December 12, 2024 | markets.businessinsider.comPrelude Therapeutics: Promising Clinical Advancements and Strong Financial Position Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comPrelude Therapeutics price target lowered to $4 from $7 at JMP SecuritiesDecember 11, 2024 | markets.businessinsider.comPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesDecember 11, 2024 | globenewswire.comPrelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitNovember 27, 2024 | globenewswire.com Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRLD Media Mentions By Week PRLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRLD News Sentiment▼1.910.92▲Average Medical News Sentiment PRLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRLD Articles This Week▼11▲PRLD Articles Average Week Get the Latest News and Ratings for PRLD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Prelude Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Aurora Cannabis News Cartesian Therapeutics News Candel Therapeutics News Monopar Therapeutics News Neumora Therapeutics News Lexeo Therapeutics News Atea Pharmaceuticals News enGene News ProQR Therapeutics News Allogene Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRLD) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
